All articles are editorially produced from primary sources. Cost, dosing, and coverage summaries are for orientation only. Verify anything material with a clinician before acting on it.
Wegovy and Zepbound affect appetite and calorie intake through different mechanisms, and each product has its own specific labeled indications.
May 23, 2026
10 min read
GLP-1 receptor agonists may help adult women with PCOS manage weight and insulin resistance, but they are not approved specifically to treat PCOS.
May 23, 2026
6 min read
Wegovy injection is taken once weekly and increased every four weeks through the first 16 weeks, usually toward a 1.7 mg or 2.4 mg maintenance dose.
May 23, 2026
8 min read
For weight-related uses, Wegovy and Zepbound should be stopped once pregnancy is recognized, because weight loss offers no benefit in pregnancy and may cause fetal harm.
May 23, 2026
7 min read
GLP-1 weight loss medications have documented benefits but also carry uncommon serious risks and important uncertainties.
May 23, 2026
8 min read
Branded drugs, compounded options, and telehealth programs all carry different costs, regulatory standing, and risks that a sticker price alone will never show you.
March 25, 2026
11 min read
People taking semaglutide and similar drugs report drinking less, and the biology is plausible, but no human clinical trial has confirmed the effect and no GLP-1 drug is approved to treat alcohol use disorder.
April 4, 2026
6 min read
The access story is no longer just about price. It is about regulation, product quality, marketing claims, and what the FDA has been signaling in public.
April 4, 2026
10 min read
Clinical guidelines treat obesity as a chronic condition, so GLP-1 medications are generally intended for long-term use, and stopping often leads to weight regain, though individual outcomes vary.
April 4, 2026
6 min read
Trial data support exercise as part of GLP-1 treatment, but no study has yet tested a specific protocol, leaving key questions about training type, intensity, and muscle preservation genuinely unanswered.
April 4, 2026
8 min read
Form Health and Mochi Health both offer online GLP-1 care, but they differ sharply on clinical structure, insurance billing, and whether medications are FDA-approved or compounded.
April 4, 2026
8 min read
The FDA found no causal link between GLP-1 medications and suicidal ideation, but questions about mood, anxiety, and long-term psychiatric effects remain genuinely unsettled.
April 4, 2026
8 min read
Tirzepatide activates both the GLP-1 and GIP receptors with a single engineered molecule, a design that produced significant weight loss in trials but whose precise mechanism in humans is still being studied.
April 4, 2026
8 min read
GLP-1 receptor agonists mimic a hormone your gut already makes, extending its effects on blood sugar, digestion, and appetite signals in the brain far longer than your body does on its own.
April 4, 2026
10 min read
List prices for both drugs top $1,000 a month, but what you actually pay depends on your insurance coverage, which manufacturer savings program you qualify for, and where you fill the prescription.
April 4, 2026
7 min read
Losing some muscle during significant weight loss is normal regardless of method, but here is what the evidence actually shows about GLP-1 medications and what you can do about it.
April 4, 2026
10 min read
Ozempic and Wegovy both contain semaglutide, but only Wegovy is FDA-approved for weight management, a distinction that directly affects insurance coverage and how each drug can be prescribed.
April 4, 2026
6 min read
Mounjaro and Zepbound both contain tirzepatide, but their different FDA approvals determine what your insurance will cover and what your doctor can prescribe without going off-label.
April 4, 2026
9 min read
GLP-1 medications slow digestion by design, and that slowing drives nausea, constipation, burping, and reflux, here is what to try at home and when to call your doctor.
April 4, 2026
13 min read
Ozempic and Wegovy both contain semaglutide, but they carry separate FDA approvals, different doses, and distinct insurance rules that make them far from interchangeable.
April 4, 2026
8 min read
GLP-1 medications suppress appetite in ways that make hitting protein targets harder and potentially more consequential, but the right amount depends on your individual situation.
April 4, 2026
7 min read
No FDA protocol exists for switching from Wegovy to Zepbound, so here is what the evidence supports, what remains uncertain, and what to ask your prescriber before making any change.
April 4, 2026
10 min read
No clinical trials or official protocols exist for switching from Zepbound to Wegovy, so here is what prescribers consider and what to ask before you make the change.
April 4, 2026
9 min read
From telehealth platforms to employer benefits, medical weight-loss programs vary widely in clinical rigor, and knowing the right questions to ask can help you tell a serious program from a prescription access funnel.
April 4, 2026
8 min read
Tirzepatide targets two gut hormone receptors while semaglutide targets one, and large clinical trials show that molecular difference translates into meaningfully different average weight loss outcomes.
April 4, 2026
8 min read
Clinical trials and real-world data tell different stories about weight regain after stopping a GLP-1 drug, and what you do next turns out to matter more than the stopping itself.
April 4, 2026
7 min read
GLP-1 drugs like Ozempic and Wegovy mimic a natural gut hormone to lower blood sugar and curb appetite, but eligibility depends on specific clinical criteria, not just interest.
April 4, 2026
9 min read
Rising costs are pushing insurers and employers to add stricter prior authorization rules and split coverage based on whether your GLP-1 is prescribed for diabetes or weight management.
April 4, 2026
11 min read
Food noise is not a formal diagnosis. It is a patient-community term for the constant mental pull of eating, planning, craving, and negotiating with appetite.
April 4, 2026
5 min read
The most common side effects are gastrointestinal, but the important distinction is between expected adaptation and persistent symptoms that need medical follow-up.
April 4, 2026
7 min read